Short Interest Watching: Is Buying Sinovac Biotech Incorporated (NASDAQ:SVA), Having Lower Short Interest a Winning Strategy?

November 17, 2016 - By Darrin Black   ·   0 Comments

Short Interest Watching: Is Buying Sinovac Biotech Incorporated (NASDAQ:SVA), Having Lower Short Interest a Winning Strategy?

The stock of Sinovac Biotech Incorporated (NASDAQ:SVA) registered a decrease of 11.1% in short interest. SVA’s total short interest was 211,500 shares in November as published by FINRA. Its down 11.1% from 237,900 shares, reported previously. With 44,800 shares average volume, it will take short sellers 5 days to cover their SVA’s short positions. The short interest to Sinovac Biotech Incorporated’s float is 0.98%. The stock increased 0.98% or $0.06 on November 16, hitting $6.17. Sinovac Biotech Ltd. (NASDAQ:SVA) has declined 3.29% since April 15, 2016 and is downtrending. It has underperformed by 7.92% the S&P500.

Sinovac Biotech Ltd. is a holding company. The company has a market cap of $351.69 million. The Firm is a biopharmaceutical firm that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. It currently has negative earnings. The Company’s pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China.

SVA Company Profile

Sinovac Biotech Ltd. (Sinovac), incorporated on March 1, 1999, is a holding company. The Firm is a biopharmaceutical firm that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company’s pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Firm is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Firm is engaged in developing various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

More notable recent Sinovac Biotech Ltd. (NASDAQ:SVA) news were published by: Prnewswire.com which released: “Sinovac Product Pipeline News” on October 19, 2016, also Benzinga.com with their article: “Sinovac Biotech Ltd. Stock Surged Amid ‘Hostile Takeover'” published on February 04, 2016, Prnewswire.com published: “Sinovac Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the …” on February 01, 2016. More interesting news about Sinovac Biotech Ltd. (NASDAQ:SVA) were released by: Benzinga.com and their article: “Heng Ren Rejects Sinovac Insider Buyout Offer” published on August 31, 2016 as well as Prnewswire.com‘s news article titled: “Sinovac Reports Unaudited Second Quarter 2016 Financial Results” with publication date: August 23, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Darrin Black


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>